The $4 million system fires countermeasure flares at speeds up to Mach 1, cutting the need for test pilots and aircraft entirely.

A satellite anomaly nicknamed the Taraia Object has drawn a 16-person Purdue-led crew to a Pacific atoll this October.

Bosma Enterprises hosts a two-day training as Meta rolls out free AI glasses to all 130,000 legally blind U.S. veterans.

Purdue’s Indianapolis expansion is being pitched as an AI-era talent pipeline for Indiana. Mitch Daniels says the real measure is how many graduates stay.

Redwire opened a 30,000‑sq‑ft microgravity R&D hub at Novaparke in Georgetown to host ISS‑linked experiments and pharma partnerships. The site includes a live payload ops center.

Eli Lilly agreed to buy AtaiBeckley for about $2.8B upfront, gaining an intranasal 5‑MeO‑DMT therapy now moving into Phase 3. The deal signals big‑pharma interest in rapid‑acting psychedelic treatments.

An IU-led coalition called IMPACT won NSF Engine backing, unlocking an initial $15M and eligibility for up to $160M to speed bone and joint innovations across Indiana.

The Department of Energy named Fishers-based American Resources among five projects in a $75M pilot to recover rare earths from coal, spotlighting central Indiana’s refining plans.

The FDA tapped seven companies — including Eli Lilly and Regeneron — for a PreCheck pilot to speed reviews of new U.S. drug plants. The cohort includes big pharma and specialized CDMOs.

IU Health opened an FDA-cleared 3D print studio at Methodist Hospital, producing patient-specific anatomical models for surgical planning and training.

Riley Hospital at IU Health used cryopreserved marrow from a deceased donor in a world‑first pediatric transplant, putting a 14‑year‑old with leukemia into remission.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

A 12‑year‑old Center Grove student is the first in Indiana to receive an FDA‑approved gene therapy at Riley, a treatment that could end her monthly transfusions.